AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06616857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NUDGE
Description: Individuals in this condition will receive intervention content to promote physical activity.
Study NCT06616857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Individuals will receive educational materials about how to increase physical activity
Study NCT06664892 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation
Description: RT, delivered via external beam, 5.2 Gy per fraction for 5 fractions following BCS and neoadjuvant or adjuvant chemotherapy. Specific adjuvant/neoadjuvant therapies are at the discretion of the treating Medical Oncologist.
Study NCT06208852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Navigator Program
Description: For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
Study NCT04602728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back2Life
Description: The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
Study NCT06482307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-olaparib PET scan
Description: The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
Study NCT05112900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Description: \[see arm/group descriptions\]
Study NCT05112900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging + Health Navigation (TM+HN)
Description: \[see arm/group descriptions\]
Study NCT05693337 — intervention group
Intervention type: DEVICE
Intervention: Forward Looking Infrared Radar (FLIR) thermal imaging
Description: The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
Study NCT06624137 — intervention group
Intervention type: DRUG
Intervention: Serotonergic Psychedelic
Description: Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects.
Study NCT06624137 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Matched Placebo
Study NCT06682234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obeldesivir
Description: Tablets administered orally
Study NCT06684080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A care bundle
Description: 1. Risk evaluation for PPH and Reserve plan;~2. Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape;~3. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered: 1） Lack of uterine contractions 2） Persistent bleeding 3）Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④~   * Maintain uterus tone (Administration of Oxytocin and second-line medications to promote uterine contraction)~     * Intravenous infusion ③ Administered tranexamic acid ④ Multi-methods and Multi-disciplinary
Study NCT06235203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgery
Description: The tumor was resected by endoscopic nasopharyngectomy.
Study NCT06235203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: The tumor was resected by endoscopic nasopharyngectomy.
Study NCT06235203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy
Description: Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
Study NCT06235203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy
Description: Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
Study NCT06235203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy
Description: Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
Study NCT06442956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Heat Condition
Description: The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
Study NCT06442956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual Heat Condition
Description: The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
Study NCT06485076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: see previous description
Study NCT06722222 — intervention group
Intervention type: PROCEDURE
Intervention: Gao's triple eversion carotid endarterectomy
Description: The carotid sheath is dissected in front of the sternocleidomastoid muscle to expose sufficient lengths of the CCA, ECA, and ICA. After raising the systolic blood pressure to 180 mmHg and intravenously injecting 1 mg/kg heparin, the superior thyroid artery is lapped and severed, and the CCA is occluded proximally to the CCA plaque, based on the plaque location shown by preoperative CTA and by intraoperative arterial exploration. Subsequently, the ECA and ICA are blocked individually. The ICA is cut diagonally at the CCA fork and the ECA is transected approximately 5 mm above its beginning. The plaque is removed with tweezers after eversion of the ICA. This process is repeated for the ECA. Finally, the long segment of plaque in the CCA is stripped proximally, followed by thorough removal of the debris on the peeling surface using heparin irrigation.
Study NCT05031702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Camellia Sinensis leaf extract
Description: 2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
Study NCT05031702 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
Study NCT06386770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
Study NCT06386770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: .Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
Study NCT06386770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Description: Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
Study NCT05735067 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: 5 ml of blood samples were withdrawn from RRMS patients
Study NCT06005766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Skills Training (MCT)
Description: The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
Study NCT06005766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
Study NCT06005766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
Study NCT05858996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain-CPG-EIT
Description: Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT.
Study NCT05858996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain-CPG-Education Only
Description: The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
Study NCT05203926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
Study NCT05670899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD PEEK frame-work
Description: Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
Study NCT05670899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAD PEEK frame-work
Description: Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
Study NCT06484478 — intervention group
Intervention type: OTHER
Intervention: Wearable technology monitoring
Description: Observational study (no intervention delivered)
Study NCT05530551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.
Study NCT05530551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic dosage practice
Description: Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.
Study NCT05552651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d1,Q3W;
Study NCT05552651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 130mg/m2,iv,D1,D8,Q3W
Study NCT05552651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5, iv,D1,Q3W
Study NCT06240962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strength Training
Description: They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
Study NCT06240962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness Exercise
Description: They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
Study NCT04967313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Change Techniques
Description: Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline.
Study NCT05547230 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: The same tests will be applied to all participants in an objective way.
Study NCT02735083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART19 follow-up
Description: UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
Study NCT05549973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study NCT04578990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient.
Study NCT04578990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength intervention
Description: The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
Study NCT04578990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent intervention
Description: The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
Study NCT05566041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001 + eLOOP Device
Description: RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy
Study NCT05566041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/carboplatin plus etoposide
Description: Standard of care platinum doublet chemotherapy